CN106176713A - The new application of α-Garcinia mangostana flavone - Google Patents
The new application of α-Garcinia mangostana flavone Download PDFInfo
- Publication number
- CN106176713A CN106176713A CN201610719034.5A CN201610719034A CN106176713A CN 106176713 A CN106176713 A CN 106176713A CN 201610719034 A CN201610719034 A CN 201610719034A CN 106176713 A CN106176713 A CN 106176713A
- Authority
- CN
- China
- Prior art keywords
- flavone
- garcinia mangostana
- group
- insulin
- diabetic groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the field of Chinese medicines, disclose the new application of α-Garcinia mangostana flavone.The invention provides α-Garcinia mangostana flavone purposes in preparation improves the medicine of islet cell function and insulin resistant, vascular endothelial function and fatty liver.Test shows, α-Garcinia mangostana flavone can improve islet cell function and insulin resistant, improve the damage of vascular tissue form and endotheliocyte edema, necrosis, come off, the phenomenon of structure disturbance, reduce liver vacuolar degeneration.Show that α-Garcinia mangostana flavone can improve islet cell function and insulin resistant, vascular endothelial function and fatty liver.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to the new application of α-Garcinia mangostana flavone, especially α-Garcinia mangostana flavone is to islets of langerhans
Cell function and the impact of insulin resistant, fatty liver and vascular endothelial function.
Background technology
Garcinia mangostana (Garcinia mangostana L.), is described as " queen in Guo ", is Guttiferae (Guttiferae) rattan
The yellow fruit belonging to (Garcinia) aiphyllium Garcinia mangostana.Originate in Indonesia and Malaysia, be a kind of typical torrid zone
Fruit, is distributed mainly on the countries in Southeast Asia such as Thailand, Vietnam, Malaysia, Indonesia, Philippine, in Guangxi China, sea
The extensively cultivation of the areas such as south.Peel of Carcinia mangostana L. is used for suffering from abdominal pain as Thailand's traditional medicine always, suffers from diarrhoea, dysentery, infected wound, change
The disease treatments such as pus, chronic ulcer, leucorrhea, gonorrhea.And, many researchs find, Garcinia mangostana has antiinflammatory, antitumor, antioxidation
Activity, and go to congratulate bacterium, escherichia coli, vibrio cholera and helicobacter pylori to staphylococcus aureus, shigella, Freund
On antibacterial, there is antibacterial activity.In recent years, chemical composition and the biologic activity thereof of Garcinia mangostana particularly peel of Carcinia mangostana L. becomes people
Study hotspot.
α-Garcinia mangostana flavone is isolated in peel of Carcinia mangostana L. mainly to have bioactive compound, and it has multiple pharmacology to make
With, as suppressed the effect of Transitional cell carcinomas (COX-2), the retarding action to Alzheimer's disease, antiinflammatory action, antioxygen to be turned into
With, suppression the effect of sphingomyelinase, cells apoptosis, histamine H1-receptor antagonism, alpha-glucosidase is pressed down
Make use, anti-pathogenic bacterium effect, phytoestrogen sample effect.
Have not yet to see α-Garcinia mangostana flavone to islet cell function and insulin resistant, fatty liver and vascular endothelial function
Relevant report.
Summary of the invention
The invention provides the new opplication of α-Garcinia mangostana flavone.
In a specific embodiment, (8 week old male db/db homozygote is little for present invention type 2 diabetes mellitus model mice
Mus) it is randomly divided into diabetic groups, α-Garcinia mangostana flavone group, select the 8 brood wild-type mices of week old as Normal group simultaneously.α-mountain
Concretio silicea Bambusae seu schizostachyi ketone group timing every day lumbar injection α-Garcinia mangostana flavone 0.3mg/kg, Normal group and diabetic groups give considerable amount of molten
Matchmaker's lumbar injection.Observe the indexs such as each group of mice ordinary circumstance, amount of drinking water, food-intake, body weight, blood glucose, observe 12 weeks altogether, terminate
((Insulin tolerance test, ITT) tests, and often organizes simultaneously and all leaves and takes fasting blood in row insulin tolerance test during experiment
Slurry, for blood glucose and insulin level detection, calculates HOMA-IR, QUICKI-IR and HOMA-β index.Along with prolonging of observing time
Long, diabetic groups mouse blood sugar substantially increases, and after α-Garcinia mangostana flavone group α-Garcinia mangostana flavone intervention, blood glucose increase ratio is not intervened
Group substantially alleviates, and illustrates that α-Garcinia mangostana flavone can delay the progress of diabetes.Diabetic groups mice HOMA-β cell function declines,
HOMA-IR substantially increases, and insulin is disposed the ability of glucose and declined (ITT).And α-Garcinia mangostana flavone group α-Garcinia mangostana flavone is done
Prognosis islet beta cell function and insulin resistant are all improved, and insulin is disposed glucose ability and made moderate progress.
Further, after mice is put to death in anesthesia, it is immediately disconnected out pancreatic tissue, makes paraffin section and see for pancreas HE dyeing
Examine Pancreas pathology to change, carry out insulin, glucagon SABC and double-labelling immunofluorescence simultaneously and observe islet function.Pancreas
The islets of langerhans of island pathological examination display Normal group mice is rounded or oval, and islet cells size is similar, is evenly distributed, in
Strand arranges, and nucleus is clear with Cytoplasm uniform dyeing, and iuntercellular separates clear.Diabetic groups mouse islets edge is irregular,
Islet cells cause not of uniform size, arranges sparse inequality, and visible cavity in bag slurry, kernel dyeing is shallow, and iuntercellular separates unintelligible.And
α-Garcinia mangostana flavone group mouse islets form is between Normal group and diabetic groups, and islet cells size is more consistent, row
Arranging more uniform, kernel dyeing is the most clear.Insulin, glucagon SABC and double-labelling immunofluorescence display Normal group
Islets of langerhans is relatively regular ellipse, and cell distribution is more uniform, and insulin stained positive regional percentage is big.Diabetic groups islets of langerhans form
Irregularly, insulin stained positive regional percentage is little, and of light color.α-Garcinia mangostana flavone group insulin stained positive area is the most extensive
Multiple.Glucagon SABC figure shows that Normal group glucagon positive region is little, and is only positioned at the periphery of islets of langerhans
Region.Diabetic groups glucagon positive region significantly increases, and occurs in the middle section of islets of langerhans.α-Garcinia mangostana flavone group is relatively
Diabetic groups has taken a turn for the better.Use image pro-plus image analysis software, calculate stained positive according to ImmunohistochemistryResults Results
Rate (stained positive area/pancreas gross area), to represent the secretion situation of insulin/glucagon in pancreas.Found that
Diabetic mice insulin/glucagon ratio compared with normal matched group is decreased obviously, insulin/pancreas after intervening with Garcinia mangostana flavone
The statistically significant rising of glucagon ratio.
The above results shows that α-Garcinia mangostana flavone can improve islet cell function and insulin resistant.
Therefore the invention provides α-Garcinia mangostana flavone in preparation improves the medicine of islet cell function and insulin resistant
Purposes.
In a specific embodiment, the present invention by BUXCO biological recorder system record continuously antiotasis change take
Each group mice thoracic aorta blood vessel records antiotasis change continuously by BUXCO biological recorder system and observes vasodilation merit
Energy.Take thoracic aorta to be dyeed by HE and electron microscopic observation endothelium ultrastructure simultaneously.Result shows, compares with Normal group,
Diabetic groups mice impaired vasodilatation.α-Garcinia mangostana flavone group arterial dilation relatively diabetic groups is improved.With the most right
Comparing according to group, diabetic groups mice blood vessel theca interna time is unintelligible, and endotheliocyte is misaligned, and form owes rule, and endothelium is thin
Cellular damage, medial thickening.And α-Garcinia mangostana flavone group vascular tissue form degree of impairment relatively diabetic groups has improvement.With normal control
Group compares, endotheliocyte edema seen from ultrastructure under diabetic groups mice Electronic Speculum, downright bad, comes off, structure disturbance.And α-Garcinia mangostana
Flavone group vascular endothelial cell ultrastructure relatively diabetic groups is improved.Show that α-Garcinia mangostana flavone can improve vascular endothelial function.
Therefore present invention also offers α-Garcinia mangostana flavone purposes in preparation improves the medicine of vascular endothelial function.
In a specific embodiment, the liver of each group mice that the present invention takes execution carries out pathologic finding, and result shows
Its hepatic tissue tactical rule of Normal group, has no obvious hepatic steatosis.Diabetes rats hepatic tissue presents substantially
The pathological change of fatty liver, lobules of liver structure owes clear, hepatocyte severe steatosis.And α-Garcinia mangostana flavone group steatosis
Lighter.Visible Normal group non-show dye under HE dyeing light microscopic；There is the red dye of large stretch of area in diabetic groups；α-Garcinia mangostana flavone
Organize red dye region and be significantly less than diabetic controls group.Show that α-Garcinia mangostana flavone has improvement result to fatty liver.
Therefore present invention also offers α-Garcinia mangostana flavone purposes in preparation improves the medicine of fatty liver.
Present invention also offers a kind of pharmaceutical preparation, comprise α-Garcinia mangostana flavone..
Further, the described α-Garcinia mangostana flavone that comprises also includes pharmaceutically acceptable adjuvant.
Described pharmaceutical preparation can be any dosage form of current medicine field, it is preferred that described pharmaceutical preparation is pill, capsule
Agent, tablet, powder, granule or oral liquid.
Each pharmaceutical dosage form can be actually needed according to this dosage form to be chosen suitably acceptable adjuvant and prepares, and this belongs to this area
Conventional dosage form technology of preparing.
As shown from the above technical solution, the invention provides α-Garcinia mangostana flavone and improve islet cell function and islets of langerhans in preparation
Purposes in the medicine of element opposing, vascular endothelial function and fatty liver.Test shows, it is thin that α-Garcinia mangostana flavone can improve islets of langerhans
Born of the same parents' function and insulin resistant, improve the damage of vascular tissue form and endotheliocyte edema, necrosis, come off, structure disturbance
Phenomenon, reduces liver vacuolar degeneration.Show that α-Garcinia mangostana flavone can improve islet cell function and insulin resistant, blood vessel endothelium
Function and fatty liver.
Accompanying drawing explanation
In order to be illustrated more clearly that the embodiment of the present invention or technical scheme of the prior art, below will be to embodiment or existing
In having technology to describe, the required accompanying drawing used is briefly described.
Fig. 1 shows embodiment 1ITT experimental result curve chart, and wherein NC group is Normal group, and DMC group is diabetic groups,
α-M group is α-Garcinia mangostana flavone group；
Fig. 2 shows embodiment 1 mouse islets immunohistochemical staining figure (400 times)；
Fig. 3 shows embodiment 1 mouse islets element SABC figure (400 times), and wherein yellow coloring district is insulin dyeing sun
The region of property, navy blue point is nucleus；
Fig. 4 shows embodiment 1 mice glucagon SABC figure (400 times), and wherein peony colour attaching area is pancreas height blood
Sugar uniformly dyeing color positive region, navy blue point is nucleus；
Fig. 5 shows embodiment 1 α/β cell proportion immunofluorescence figure (400 times), and wherein red fluorescence is insulin labelling, green
Color fluorescence is glucagon labelling, and blue-fluorescence is nuclear marker；
Fig. 6 shows the endothelium-dependent vasodilatation function comparison diagram of the mouse aorta under embodiment 2 different condition, wherein
Abscissa is the logarithm value of acetylcholine concentration, and vertical coordinate is vasodilative percentage ratio.Normal group is brood wild-type mice,
Diabetic groups is diabetic mice (solvent is without Garcinia mangostana flavone injection group), and intervention group is that the diabetes that α-Garcinia mangostana flavone is intervened are little
Mus；
Fig. 7 shows embodiment 2 vascular endothelial cell microexamination figure；
Fig. 8 shows embodiment 2 vascular endothelial cell electron microscopic observation figure；
Fig. 9 shows embodiment 3 mouse liver pathologic finding figure, and wherein figure A is diabetic groups (200 times), and figure B is diabetic groups
(400 times), figure C is α-Garcinia mangostana flavone group (200 times), and figure D is α-Garcinia mangostana flavone group (400 times).
Detailed description of the invention
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the present invention rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under not making creative work premise, all
Belong to the scope of protection of the invention.
In order to be better understood from the present invention, below in conjunction with specific embodiment, the present invention is described in detail.As without feature
Illustrating in above example, each component is commercial goods.
Embodiment 1, islet function are studied
1. experimental technique
It is randomly divided into diabetic groups, α-Garcinia mangostana with type 2 diabetes mellitus model mice (8 week old male db/db homozygote mice)
Flavone group, selects the 8 brood wild-type mices of week old as Normal group simultaneously.α-Garcinia mangostana flavone group timing every day lumbar injection α-
Garcinia mangostana flavone 0.3mg/kg, Normal group and diabetic groups give considerable amount of solvent lumbar injection.Observe each group of mice one
As the index such as situation, amount of drinking water, food-intake, body weight, blood glucose, observe 12 weeks altogether, row insulin tolerance test when terminating testing
(Insulin tolerance test, ITT) tests, and often organizes simultaneously and all leaves and takes fasting plasma for blood glucose and insulin level inspection
Survey, calculate HOMA-IR, QUICKI-IR and HOMA-β index.
Wherein, HOMA-IR=FBS*FINS/22.5,
QUICKI-IR=1/ [log (FIns)+log (FBS)],
HOMA-β=20*I0/ (G0-3.5) (%)
After mice is put to death in anesthesia, it is immediately disconnected out pancreatic tissue, the tail of pancreas fixing rear wax embedding of 4% paraformaldehyde, row 4
μm serial section, observes Pancreas pathology for pancreas HE dyeing and changes, insulin, glucagon SABC and the immunity of double mark
Fluirescence observation islet function.
2. experimental result
2.1 laboratory animal ordinary circumstances compare
Normal group mouse body is in good condition, body weight with week old increase, figure freely, flexible movements.Diabetic groups,
α-Garcinia mangostana flavone group mouse body state is poor.Two groups of Mouse Weight compared with normal matched groups are the fattest, " polydipsia, polyuria, many
Food " symptom is obvious, slow movement, sluggish, the withered and yellow tarnish of hair.2.2 respectively organize mice amount of drinking water compares
Before α-Garcinia mangostana flavone is intervened, the db/db mice of diabetic groups and α-Garcinia mangostana flavone group is compared with the normal control of NC group
Group mice amount of drinking water substantially increases.After injection α-Garcinia mangostana flavone 6 weeks, α-Garcinia mangostana flavone group amount of drinking water relatively diabetic groups is decreased obviously
(P ＜ 0.05), after injection α-Garcinia mangostana flavone 12 weeks, the amount of drinking water of α-Garcinia mangostana flavone group declines (P ＜ 0.05) further, refers to table
1。
Table 1 inject α-Garcinia mangostana flavone 0 week, 1 week, 6 weeks, the amount of drinking water of 12 weeks compare (ml/d, X ± S)
| Group | Number of cases | 0w | 1w | 6w | 12w |
| Normal group | 12 | 26.4±2.6# | 28.4±3.1# | 31.9±3.4# | 33.6±3.5# |
| Diabetic groups | 12 | 53.8±4.1* | 58.3±4.7* | 74.7±8.3* | 80.2±8.2* |
| α-Garcinia mangostana flavone group | 12 | 55.6±3.8* | 56.9±4.4* | 66.5±6.7*# | 59.4±7.1*# |
Note: " * represents P < 0.05 compared with Normal group,#Represent P < 0.05 compared with diabetic groups
2.3 respectively organize mice food-intake compares
Before α-Garcinia mangostana flavone is intervened, the mice food-intake of the db/db mice compared with normal matched group of diabetic groups substantially increases
Add.After injection α-Garcinia mangostana flavone 6 weeks, α-Garcinia mangostana flavone group food-intake begins with downward trend.After injection α-Garcinia mangostana flavone 12 weeks,
α-Garcinia mangostana flavone group food-intake is decreased obviously (P ＜ 0.05), refers to table 2.
Table 2 inject α-Garcinia mangostana flavone 0 week, 1 week, 6 weeks, the food-intake of 12 weeks compare (g/d,)
| Group | Number of cases | 0w | 1w | 6w | 12w |
| Normal group | 12 | 21.6±2.1# | 22.7±2.9# | 27.4±2.5# | 32.8±3.1# |
| Diabetic groups | 12 | 45.2±4.4* | 46.4±4.2* | 55.9±4.3* | 60.5±4.7* |
| α-Garcinia mangostana flavone group | 12 | 46.1±3.4* | 46.2±3.8* | 52.8±5.7* | 50.2±4.6*# |
Note: * represents P < 0.05 compared with Normal group,#Represent P < 0.05 compared with diabetic groups.
2.4 respectively group Mouse Weight changes
Before α-Garcinia mangostana flavone is intervened, db/db Mouse Weight compared with normal matched group significantly raised (P ＜ 0.05).Injection α-
Diabetic groups still compared with normal matched group significantly raised (P ＜ 0.05) after Garcinia mangostana flavone, α-Garcinia mangostana flavone group body weight raises relatively glycosuria
Sick group substantially (P ＜ 0.05), refers to table 3.
Table 3 respectively organize mice α-Garcinia mangostana flavone patients before and after intervention weight ratio relatively (g,)
| Group | Number of cases | Body weight before intervening | 12 weeks body weight after intervention |
| Normal group | 12 | 19.8±1.89# | 24.6±2.24# |
| Diabetic groups | 12 | 35.8±1.83* | 43.6±5.58* |
| α-Garcinia mangostana flavone group | 12 | 34.5±2.33* | 47.6±3.41*# |
Note: * represents P < 0.05 compared with Normal group,#Represent P < 0.05 compared with diabetic groups.
2.5 change of blood sugar
Add up each group of change of blood sugar and the results are shown in Table 4
4 three groups of mouse blood sugar levels of table
| Group | Number of cases | Blood glucose (mmol/l) before intervening | 12 weeks blood glucose (mmol/l) after intervention |
| Normal group | 12 | 8.73±2.00 | 8.44±2.30 |
| Diabetic groups | 12 | 20.66±4.28a | 36.51±9.20a |
| α-Garcinia mangostana flavone group | 12 | 22.14±5.61a | 15.94±2.21ab |
Note:aRepresent P < 0.05 compared with Normal group,bRepresent P < 0.05 compared with diabetic groups.
Table 4 result shows that diabetic groups and α-Garcinia mangostana flavone group blood glucose are obviously higher than normally before α-Garcinia mangostana flavone is intervened
Matched group.Along with the prolongation of observing time, diabetes are gradually in progress, and diabetic groups blood glucose raises further, and α-Garcinia mangostana flavone
Group blood glucose substantially reduces with diabetic groups before relatively self intervenes, and illustrates that α-Garcinia mangostana flavone has reduction blood glucose, delays diabetes development
Effect.
2.6 insulin tolerance test results are shown in Fig. 1
Result shows, diabetic groups mouse islets element is disposed the ability compared with normal matched group of glucose and declined, and blood glucose is obvious
Increase, and dispose glucose ability with insulin after α-Garcinia mangostana flavone intervention and make moderate progress.
2.7 insulin resistance index
Insulin resistance index HOMA-IR, QUICKI-IR and index of β-cell function in HOMA HOMA-β the results are shown in Table 5.
Table 5 insulin resistance index and index of β-cell function in HOMA
| Group | Log10HOMA-IR | Log10QUICKI-IR | Log10HOMA-β |
| Normal group | 0.47±0.042# | -0.26±0.010# | 1.62±0.293# |
| Diabetic groups | 1.59±0.046* | -0.47±0.068* | 1.12±0.263* |
| α-Garcinia mangostana flavone group | 1.04±0.152*# | -0.38±0.069*# | 1.51±0.263# |
Note: * represents and compares with Normal group, P ＜ 0.05；#Represent and compare P ＜ 0.05 with diabetic groups
Result display diabetic mice HOMA-β cell function declines, and HOMA-IR substantially increases, and intervenes with α-Garcinia mangostana flavone
Rear islet beta cell function and insulin resistant are all improved.
2.8 pancreas HE coloration results are shown in Fig. 2
Fig. 2 result shows, the islets of langerhans of Normal group mice is rounded or oval, and islet cells size is similar, distribution
Uniformly, arranging in strand, nucleus is clear with Cytoplasm uniform dyeing, and iuntercellular separates clear.Diabetic groups mouse islets edge
Irregularly, islet cells cause not of uniform size, arrange sparse inequality, visible cavity in bag slurry, kernel dyeing is shallow, and iuntercellular separates not
Clearly.And α-Garcinia mangostana flavone group mouse islets form is between Normal group and diabetic groups, islet cells size is more
Unanimously, arranging more uniform, kernel dyeing is the most clear.
2.9 insulins, glucagon SABC and double-labelling immunofluorescence
Insulin, glucagon ImmunohistochemistryResults Results are shown in Fig. 3 and 4
Fig. 3 insulin SABC figure shows that Normal group islets of langerhans is relatively regular ellipse, and cell distribution is more uniform,
Insulin stained positive regional percentage is big.Diabetic groups islets of langerhans form is irregular, and insulin stained positive regional percentage is little and face
Color is shallow.α-Garcinia mangostana flavone group insulin stained positive area has recovered.
Fig. 4 glucagon SABC figure shows that Normal group glucagon positive region is little, and is only positioned at pancreas
The neighboring area on island.Diabetic groups glucagon positive region significantly increases, and occurs in the middle section of islets of langerhans.α-Garcinia mangostana
Flavone group relatively diabetic groups has taken a turn for the better.
Insulin, glucagon double-labelling immunofluorescence result are shown in Fig. 5.Statistical result is shown in Table 6.
Table 6 mouse islets element, glucagon SABC and double-labelling immunofluorescence results contrast
| Group | Number of cases | Insulin positive rate (%) | Glucagon positive rate (%) | Beta/alpha cell proportion |
| Normal group | 12 | 78.00% ± 0.021 | 4.28% ± 0.014 | 5.65±1.69 |
| Diabetic groups | 12 | 51.24% ± 0.064a | 10.55% ± 0.035a | 2.77±1.48a |
| α-Garcinia mangostana flavone group | 12 | 62.88% ± 0.105a | 6.33% ± 0.064ab | 4.06±1.59ab |
Note:aRepresent P < 0.05 compared with Normal group,bRepresent P < 0.05 compared with diabetic groups.
Table 6 result shows, compares with Normal group mice, and diabetic groups, α-Garcinia mangostana flavone group mouse islets element is positive
Rate reduces the most statistically significant (P ＜ 0.05), but α-Garcinia mangostana flavone group insulin positive rate relatively diabetic controls group has statistics
Meaning increases.The result of glucagon SABC shows, compares with Normal group mice, diabetic controls group, α-
Garcinia mangostana flavone group mice glucagon positive rate increases the most statistically significant (P ＜ 0.05), but does through α-Garcinia mangostana flavone group
Prognosis glucagon positive rate is compared with the statistically significant decline of diabetic controls group.Use image pro-plus graphical analysis
Software, calculates stained positive rate (stained positive area/pancreas gross area) according to ImmunohistochemistryResults Results, to represent beta/alpha in pancreas
Ratio.Found that diabetic mice beta/alpha ratio compared with normal matched group is decreased obviously, beta/alpha after intervening by α-Garcinia mangostana flavone group
The statistically significant rising of ratio.
Embodiment 2, vascular endothelial function are studied
Example 1 is respectively organized mice and is opened breast under anaesthesia respectively, after heart extracting blood, is rapidly separated, clip thoracic aorta, puts
In being filled with 95%O2And 5%CO2In the krebs solution of mixed gas improvement.Carefully cut off surrounding connective tissue, remove Ink vessel transfusing blood
Liquid, is cut into the vascular ring of 3-4mm, and bath is fixed in one end, and the other end connects tonotransducer, by BUXCO biological recorder system
System record antiotasis change continuously.Vascular ring is placed in 8ml and is full of 95%O2And 5%CO2The water of the improvement krebs solution of mixed gas
In groove (37 DEG C), changed 1 krebs solution every 15 minutes.Rest tension is 1g, balances 60 minutes, adds with KCl (60mmol/L)
Vasoconstrictive, after rinsing 2-3 time, rebalancing vascular ring, with phyenlephrinium (10-6M) vasoconstrictive, observes tired after stable
The acetylcholine (10 of volume concentrations-8～10-6M) inducing endothelial dependency vasodilation.Result is shown in Fig. 6.
Each concentration Endotheli-um-dependent Vasodilatation (EDVR)=maximum tension-each concentration point tension force/(maximum tension-
Basic value) × 100%
Separately leaving and taking thoracic aorta HE dyeing, electron microscopic observation endothelium ultrastructure result is shown in Fig. 7 and Fig. 8.
Fig. 6 shows and compares with Normal group, diabetic groups mice impaired vasodilatation.And α-Garcinia mangostana flavone group is used
After α-Garcinia mangostana flavone is intervened, arterial dilation relatively diabetic groups is improved.
Fig. 7 result display diabetic groups mice blood vessel theca interna time is unintelligible, and endotheliocyte is misaligned, and form owes rule
Then, endothelial cell damage, medial thickening.α-Garcinia mangostana flavone group vascular tissue form degree of impairment relatively diabetic groups is improved.
Fig. 8 compares with Normal group, endotheliocyte edema seen from ultrastructure under diabetic groups mice Electronic Speculum, downright bad,
Come off, structure disturbance.And α-Garcinia mangostana flavone group vascular endothelial cell ultrastructure relatively diabetic groups is improved.
Embodiment 3, impact on fatty liver
The liver of the mice that Example 1 respectively organizes execution carries out HE dyeing pathologic finding respectively, and result is shown in Fig. 9.
Result display its hepatic tissue tactical rule of Normal group, has no obvious hepatic steatosis.Diabetic groups is big
Rat liver presents the pathological change of obvious fatty liver, and lobules of liver structure owes clear, hepatocyte severe steatosis.And α-mountain
Concretio silicea Bambusae seu schizostachyi ketone group steatosis is lighter.Visible Normal group non-show dye under HE dyeing light microscopic；There is large stretch of area in diabetic groups
Red dye；α-Garcinia mangostana flavone group red dye region is significantly less than diabetic controls group.Show that α-Garcinia mangostana flavone has improvement to fatty liver
Effect.
Claims (6)
1. α-Garcinia mangostana flavone purposes in preparation improves the medicine of islet cell function and insulin resistant.
2. α-Garcinia mangostana flavone purposes in preparation improves the medicine of vascular endothelial function.
3. α-Garcinia mangostana flavone purposes in preparation improves the medicine of fatty liver.
4. a pharmaceutical preparation, it is characterised in that comprise α-Garcinia mangostana flavone.
Pharmaceutical preparation the most according to claim 4, it is characterised in that also comprise pharmaceutically acceptable adjuvant.
Pharmaceutical preparation the most according to claim 5, it is characterised in that it is pill, capsule, tablet, powder, granule
Or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610719034.5A CN106176713A (en) | 2016-08-24 | 2016-08-24 | The new application of α-Garcinia mangostana flavone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610719034.5A CN106176713A (en) | 2016-08-24 | 2016-08-24 | The new application of α-Garcinia mangostana flavone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106176713A true CN106176713A (en) | 2016-12-07 |
Family
ID=57523571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610719034.5A Pending CN106176713A (en) | 2016-08-24 | 2016-08-24 | The new application of α-Garcinia mangostana flavone |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106176713A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109453161A (en) * | 2018-12-20 | 2019-03-12 | 郑州大学 | α-, β-and application of the γ-mangostin as LSD1 inhibitor in drug |
| CN115068451A (en) * | 2021-03-15 | 2022-09-20 | 中国医学科学院药物研究所 | Medical application of hypocrellin compound as LTB4 receptor inhibitor |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101428045A (en) * | 2007-11-06 | 2009-05-13 | 王莉 | Novel medicament of plants for treating multiple diseases of female reproductive system |
| CN101612147A (en) * | 2009-07-24 | 2009-12-30 | 中山大学 | The application of α-mangostin in the preparation anti-inflammation analgesis medicament |
| CN102151258A (en) * | 2011-02-18 | 2011-08-17 | 夏铮 | Application of Alpha-mangostin in preparing medicines for treating Alzheimer's disease |
| CN102670581A (en) * | 2011-03-08 | 2012-09-19 | 吉林农业大学 | Application of alpha-mangostin for prevention and treatment of diabetes mellitus |
-
2016
- 2016-08-24 CN CN201610719034.5A patent/CN106176713A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101428045A (en) * | 2007-11-06 | 2009-05-13 | 王莉 | Novel medicament of plants for treating multiple diseases of female reproductive system |
| CN101612147A (en) * | 2009-07-24 | 2009-12-30 | 中山大学 | The application of α-mangostin in the preparation anti-inflammation analgesis medicament |
| CN102151258A (en) * | 2011-02-18 | 2011-08-17 | 夏铮 | Application of Alpha-mangostin in preparing medicines for treating Alzheimer's disease |
| CN102670581A (en) * | 2011-03-08 | 2012-09-19 | 吉林农业大学 | Application of alpha-mangostin for prevention and treatment of diabetes mellitus |
Non-Patent Citations (3)
| Title |
|---|
| AMPORN JARIYAPONGSKUL 等: "Alpha-Mangostin Attenuation of Hyperglycemia-Induced Ocular Hypoperfusion and Blood Retinal Barrier Leakage in the Early Stage of Type 2 Diabetes Rats", 《BIOMED RESEARCH INTERNATIONAL》 * |
| KANJANA JITTIPORN 等: "Anti-angiogenic actions of the mangosteen polyphenolic xanthone derivative α-mangostin", 《MICROVASCULAR RESEARCH》 * |
| YOUNG HEE CHOI 等: "α-Mangostin Regulates Hepatic Steatosis and Obesity through SirT1-AMPK and PPARγ Pathways in High-Fat Diet-Induced Obese Mice", 《JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109453161A (en) * | 2018-12-20 | 2019-03-12 | 郑州大学 | α-, β-and application of the γ-mangostin as LSD1 inhibitor in drug |
| CN115068451A (en) * | 2021-03-15 | 2022-09-20 | 中国医学科学院药物研究所 | Medical application of hypocrellin compound as LTB4 receptor inhibitor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102316884B (en) | Fraction of melissa leaf extract having angiogenesis and MMP inhibitory activities, and composition comprising the same | |
| CN106176713A (en) | The new application of α-Garcinia mangostana flavone | |
| CN102274173B (en) | Novel anticoccidial agent adprin solution and preparation method thereof | |
| RathnaKumari et al. | Antibacterial efficacy of seagrass Cymodocea serrulata-engineered silver nanoparticles against prawn pathogen Vibrio parahaemolyticus and its combative effect on the marine shrimp Penaeus monodon | |
| CN109576176A (en) | A kind of nanometer selenium bifidobacterium longum and its preparation method and application | |
| TWI484966B (en) | Extraction process for caulerpa lentillifera extract and pharmaceutical composition containing caulerpa lentillifera extract for inhibiting growth of prostate cancer cells | |
| Suffi et al. | The medicinal benefits, phytochemical constituents and antioxidant properties of banana blossom: A mini review | |
| US20230057861A1 (en) | Use of corydalis saxicola bunting and formulation thereof in preparation of drug for treating non-alcoholic fatty liver diseases | |
| CN103301235A (en) | Traditional Chinese medicine preparation for treating anemofrigid-damp arthralgia and arthralgia and preparation method thereof | |
| CN105078964A (en) | Application of artesunate in preparation of medicine for treating idiopathic pulmonary fibrosis | |
| Mirancea et al. | Relevant infrastructural alterations in a pancreatic neuroendocrine tumor: an insulinoma case | |
| CN104262463A (en) | Silkworm pupa polypeptide as well as preparation method and application thereof | |
| CN104800321B (en) | The application of dark plum and its extract in preventing and treating bowelcancer medicine or health products are prepared | |
| CN106999596A (en) | Cynara scolymus titration extract and application thereof | |
| CN106074585B (en) | Ginsenoside Rb1 and Rd combination and its application in the drug of preparation treatment photoreceptor cell death related disease | |
| Kusriani et al. | Antidiabetic Activity of Combination of Binahong (Anredera cordifolia Ten. Steenis), Cherry (Muntingia calabura L.) and Brotowali (Tinospora crispa L.) Extracts | |
| CN100455299C (en) | Application of cultured saussurea medusa and extract thereof in preparation of medicine for treating II type diabetes and its complications | |
| Yusuf et al. | Histological study on the effects of aqueous extracts of citron leaf on pancreas of hyperglycemic wistar rats | |
| CN108514557B (en) | Application of the rotenone in pancreas islet protection | |
| CN110393716A (en) | Application of the fangchinoline in the drug that preparation inhibits lung cancer metastasis | |
| KINSMAN et al. | Fulminating meningococcic septicemia associated with adrenal lesions: an analysis and discussion of seven cases | |
| CN112494487A (en) | Application of hirsutine in preparation of medicines for improving insulin resistance, diabetes and complications thereof | |
| CN108348561A (en) | Medicinal artemisiifolia genus plants extract | |
| CN106074474A (en) | Benserazide and pharmaceutically application in terms of preparing antineoplastic for the acceptable salt | |
| Kognou et al. | Antioxidant, analgesic and antipyretic activities of ethanol extract of the stem bark Dichaetanthera africana (Hooker F.) Jacq. Felix.(Melastomataceae) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161207 |
|
| RJ01 | Rejection of invention patent application after publication |